Biostatistics and Bioinformatics Core Director: Venkatraman E. Seshan, PhD CORE SUMMARY The role of the Biostatistics and Bioinformatics Core is to support the investigators of the SPORE in Lymphoma in their research efforts, including laboratory experiments, molecular studies and the design and analysis of clinical trials. In laboratory experiments, core members will assist in the formulation of the experimental design and in the analysis and interpretation of the data at the conclusion of the study. In molecular studies, Core members will closely interface with the members of the Biospecimen Repository Core, and will have primary responsibility of merging molecular and clinical data, followed by appropriate statistical analysis and reporting. In the clinical trial design phase, a core member will conduct a protocol review with the principal investigator. Based on this, a statistical section for the protocol will be provided, outlining major scientific objectives, population to be studied, primary and secondary endpoints, experimental design, a randomization procedure if necessary, analysis plans, and a targeted sample size justified in probabilistic terms. At the conclusion of the trial, data analyses will be performed to assess outcomes of the primary and secondary endpoints stated in the protocol. If current statistical methodology does not adequately address a research question in this SPORE, alternative methodologies will be explored.
Specific Aim 1 : To provide statistical and bioinformatic expertise in experimental design, data analysis and interpretation. The core will be involved in the studies from the conception stage all the way to its completion and dissemination.
Specific Aim 2 : To develop and/or adapt and implement novel statistical and bioinformatic methodologies to meet need when standard methods are less than optimal.
Specific Aim 3 : To provide informatics infrastructure to enable collaboration and data sharing among the various projects and the three institutions that constitute this spore.
|Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141|
|Pasqualucci, Laura; Dalla-Favera, Riccardo (2018) Genetics of diffuse large B-cell lymphoma. Blood 131:2307-2319|
|Joshi, Suhasini; Wang, Tai; Araujo, Thaís L S et al. (2018) Adapting to stress - chaperome networks in cancer. Nat Rev Cancer 18:562-575|
|Kishinevsky, Sarah; Wang, Tai; Rodina, Anna et al. (2018) HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. Nat Commun 9:4345|
|Rafiq, Sarwish; Yeku, Oladapo O; Jackson, Hollie J et al. (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36:847-856|
|Lu, Xiaoqing; Fernando, Tharu M; Lossos, Chen et al. (2018) PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood 132:2026-2039|
|Kaittanis, Charalambos; Andreou, Chrysafis; Hieronymus, Haley et al. (2018) Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med 215:159-175|
|Liu, Yuxuan; Mondello, Patrizia; Erazo, Tatiana et al. (2018) NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Proc Natl Acad Sci U S A 115:12034-12039|
|Intlekofer, Andrew M; Joffe, Erel; Batlevi, Connie L et al. (2018) Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J 8:60|
|Guo, A; Lu, P; Lee, J et al. (2017) HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. Oncogene 36:3441-3449|
Showing the most recent 10 out of 28 publications